Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Coherus BioSciences Inc.

    NASDAQ: CHRS · Real-Time Price · USD
    0.78
    0.02 (2.40%)
    At close: Jun 16, 2025, 3:59 PM
    0.78
    1.13%
    Pre-market: Jun 17, 2025, 06:45 AM EDT

    Coherus BioSciences Statistics

    Share Statistics

    Coherus BioSciences has 115.93M shares outstanding. The number of shares has increased by 1.02% in one year.

    Shares Outstanding

    n/a
    		 115.93M

    Shares Change (YoY)

    n/a
    		 1.02%

    Shares Change (QoQ)

    n/a
    		 0.59%

    Owned by Institutions (%)

    n/a
    		 56.94%

    Shares Floating

    n/a
    		 111.43M

    Failed to Deliver (FTD) Shares

    n/a
    		 115

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 32.53M, so 28.06% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 32.53M

    Short % of Shares Out

    n/a
    		 28.06%

    Short % of Float

    n/a
    		 29.18%

    Short Ratio (days to cover)

    n/a
    		 30.12

    Valuation Ratios

    The PE ratio is 5.55 and the forward PE ratio is -0.93. Coherus BioSciences's PEG ratio is -0.05.

    PE Ratio

    n/a
    		 5.55

    Forward PE

    n/a
    		 -0.93

    PS Ratio

    n/a
    		 0.59

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 -1.2

    P/FCF Ratio

    n/a
    		 -7.73

    PEG Ratio

    n/a
    		 -0.05
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Coherus BioSciences.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.21, with a Debt / Equity ratio of -2.04.

    Current Ratio

    n/a
    		 1.21

    Quick Ratio

    n/a
    		 0.96

    Debt / Equity

    n/a
    		 -2.04

    Debt / EBITDA

    n/a
    		 4.43

    Debt / FCF

    n/a
    		 -13.2

    Interest Coverage

    n/a
    		 -4.11

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,170,877.19

    Profits Per Employee

    n/a
    		 $125,030.7

    Employee Count

    n/a
    		 228

    Asset Turnover

    n/a
    		 0.6

    Inventory Turnover

    n/a
    		 1.68

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -52.44% in the last 52 weeks. The beta is 0.88, so Coherus BioSciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.88

    52-Week Price Change

    n/a
    		 -52.44%

    50-Day Moving Average

    n/a
    		 0.89

    200-Day Moving Average

    n/a
    		 1.08

    Relative Strength Index (RSI)

    n/a
    		 44.11

    Average Volume (20 Days)

    n/a
    		 1,685,988

    Income Statement

    In the last 12 months, Coherus BioSciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.

    Revenue

    n/a
    		 266.96M

    Gross Profit

    n/a
    		 149.41M

    Operating Income

    n/a
    		 -111.67M

    Net Income

    n/a
    		 28.51M

    EBITDA

    n/a
    		 60.94M

    EBIT

    n/a
    		 55.66M

    Earnings Per Share (EPS)

    n/a
    		 0.25
    Full Income Statement

    Balance Sheet

    The company has 125.99M in cash and 269.9M in debt, giving a net cash position of -143.92M.

    Cash & Cash Equivalents

    n/a
    		 125.99M

    Total Debt

    n/a
    		 269.9M

    Net Cash

    n/a
    		 -143.92M

    Retained Earnings

    n/a
    		 -1.55B

    Total Assets

    n/a
    		 371.07M

    Working Capital

    n/a
    		 55.13M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -20.44M and capital expenditures 0, giving a free cash flow of -20.44M.

    Operating Cash Flow

    n/a
    		 -20.44M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -20.44M

    FCF Per Share

    n/a
    		 -0.18
    Full Cash Flow Statement

    Margins

    Gross margin is 55.97%, with operating and profit margins of -41.83% and 10.68%.

    Gross Margin

    n/a
    		 55.97%

    Operating Margin

    n/a
    		 -41.83%

    Pretax Margin

    n/a
    		 10.68%

    Profit Margin

    n/a
    		 10.68%

    EBITDA Margin

    n/a
    		 22.83%

    EBIT Margin

    n/a
    		 -41.83%

    FCF Margin

    n/a
    		 -7.66%

    Dividends & Yields

    CHRS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CHRS is $6, which is 669.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 669.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $1.25

    Lynch Upside

    n/a
    		 60.26%

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -6.18

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist